-+ 0.00%
-+ 0.00%
-+ 0.00%

First Berlin reiterates Buy on Cardiol Therapeutics, cuts price target to USD 7.5

PUBT·04/17/2026 13:31:59
Listen to the news
First Berlin reiterates Buy on Cardiol Therapeutics, cuts price target to USD 7.5
  • First Berlin Equity Research cut Cardiol Therapeutics price target to USD 7.5 from USD 7.8 while reiterating Buy.
  • Update followed Cardiol Therapeutics FY/25 results, described as broadly in line with expectations.
  • Analyst flagged MAVERIC Phase III trial in recurrent pericarditis as on track for full enrollment in Q2 2026.
  • Report kept focus on expected Q4 2026 headline readout for MAVERIC.
  • First Berlin cited January 2026 capital raise extending cash runway to Q4 2027, citing higher dilution as driver of target cut.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cardiol Therapeutics Inc. published the original content used to generate this news brief via EQS News, a service of EQS Group AG (Ref. ID: rc_25448), on April 17, 2026, and is solely responsible for the information contained therein.